109249-29-8

Basic information

• Product Name: 3H-Pyrazol-3-one, 5-ethyl-1,2-dihydro-1-methyl-2-phenyl-
• CAS NO: 109249-29-8
• Molecular Formula: C12H14N2O
• Molecular Weight: 202.256
• Mol File: 109249-29-8.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 3H-Pyrazol-3-one, 5-ethyl-1,2-dihydro-1-methyl-2-phenyl-(CAS DataBase Reference)
• NIST Chemistry Reference: 3H-Pyrazol-3-one, 5-ethyl-1,2-dihydro-1-methyl-2-phenyl-(109249-29-8)
• EPA Substance Registry System: 3H-Pyrazol-3-one, 5-ethyl-1,2-dihydro-1-methyl-2-phenyl-(109249-29-8)

Safety Data

• Hazardous Substances Data: 109249-29-8(Hazardous Substances Data)

Upstream product

• 100-63-0 phenylhydrazine 
• 21633-77-2 diethyl 2-propionylmalonate 
• 4949-44-4 ethyl propanoylacetate 
• 80-48-8 methyl p-toluene sulfonate 
• 92753-34-9 2-phenyl-5-ethyl-2,4-dihydro-3H-pyrazol-3-one 
• 60-80-0 antipyrine 
• 74-88-4 methyl iodide 
• 916319-06-7 5-ethyl-2-phenyl-1,2-dihydro-pyrazol-3-one 

Relevant articles and documents

Regiospecific generation and application of 3-lithiomethyl-2-methyl-1-phenylpyrazolin-5-one as 1,3-binucloephile in aromatic annelation: A novel approach for synthesis of 1,2-disubstituted indazolones and their condensed analogs

The enolate anion 5A generated by deprotonation of 2,3-dimethyl-1-phenylpyrazolin-5-one is shown to undergo highly regioselective γ-1,4-addition to α-oxoketene dithioacetals followed by cycloaromatization in the presence of boron trifluoride etherate to afford wide range of novel substituted and condensed indazolones in good yields.

PYRAZOLONE COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR AGONISTS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS

Compounds of Formula (I), wherein R1, R2, R3, R4, R5, R6, X, and n are as defined for Formula (I) in the description, processes for the preparation of the compounds and new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and the use of the compounds in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction.